Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells

Acta Haematologica

Volumn 132, Issue 1, 2014, Pages 1-4

  Sripayap, Piyanuch ^a   Nagai, Tadashi ^a   Hatano, Kaoru ^a   Kikuchi, Jiro ^a   Furukawa, Yusuke ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; BORTEZOMIB; CELL ADHESION MOLECULE; DEXAMETHASONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; LIPOCORTIN 5; MELPHALAN; ROMIDEPSIN; SYNDECAN 1; AZACITIDINE; CHEMOKINE RECEPTOR CXCR4; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; COCULTURE; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; ALPHA4 INTEGRIN GENE; CANCER CELL LINE; CELL ADHESION MEDIATED DRUG RESISTANCE; DRUG MECHANISM; DRUG RESISTANCE; GENE; HUMAN CELL;

ANTIGENS, CD29; BORONIC ACIDS; CELL ADHESION; CELL LINE; DEPSIPEPTIDES; DEXAMETHASONE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTEGRIN ALPHA4; MELPHALAN; MULTIPLE MYELOMA; PYRAZINES; RNA, MESSENGER; RNA, NEOPLASM; SYNDECAN-1;

EID: 84890494829     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000357213     Document Type: Article

References (12)

1. Gentile M, Recchia AG, Mazzone C, Lucia E, Vigna E, Morabito F: Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013; 13(suppl 1):S1-S22.
2. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
3. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K: Bortezomib overcomes cell-adhesionmediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231-242.
4. Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107: 600-608.
5. Christman JK: 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-5495.
6. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008; 14: 826-832.
7. Rosen GD, Barks JL, Iademarco MF, Fisher RJ, Dean DC: An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the alpha 4 integrin gene promoter. J Biol Chem 1994; 269: 15652-15660.
8. Kirschner KM, Wagner N, Wagner KD, Wellmann S, Scholz H: The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the α4integrin gene. J Biol Chem 2006; 281: 31930-31939.
9. Pei XY, Dai Y, Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839-3852.
10. Kaufman JL, Fabre C, Lonial S, Richardson PG: Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 2013; 13: 370-376.
11. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC: Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013; 37: 829-837.
12. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y: Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116: 406-417.